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Abstract
Background: The prevalence of ischemia on nuclear myocardial perfusion imaging (MPI) has been decreasing. Recent
research has questioned the benefit of invasive revascularization for patients with moderate to severe ischemia. We
hypothesized that patients with moderate to severe ischemia could routinely undergo successful revascularization.
Methods: We analyzed data from 544 patients who underwent an MPI at a single academic Veterans Affairs Medical
Center. Patients with moderate to severe ischemia, defined as a summed difference score (SDS) 8 or greater,
were compared to the rest of the cohort.
Results: Of the total cohort (n = 544), 39 patients had MPI studies with resultant moderate to severe ischemia.
Patients with ischemia were more likely to develop coronary artery disease (74.4% versus 38.8%, P < 0.0001) and have
successful revascularization (38.5% versus 4.0%, P < 0.0001) during the following year. Revascularization was attempted
in 31 patients with moderate to severe ischemia, though only 15 (47%) of these attempts were successful. Ischemia
was predictive of myocardial infarction (5.1% versus 0.8%, P = 0.01) within 1 year.
Conclusion: Moderate to severe ischemia is an uncommon finding in a contemporary nuclear laboratory. Among
patients with ischemia, revascularization is typically attempted but is frequently unsuccessful.
Trial registration: This trial does not appear on a registry as it is neither randomized nor prospective.
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Background
Myocardial perfusion imaging (MPI), which detects myo-
cardial ischemia, is reliable at detecting obstructive coron-
ary artery disease (CAD) [1]. When the MPI is normal,
patients are at a lower risk for cardiovascular events, usu-
ally for at least 1 year following the test [2]. When MPI
demonstrates a large burden of myocardial ischemia, co-
hort evidence suggests that revascularization is superior to
medical therapy for reducing cardiovascular events [3]. As
such, MPI is commonly used to decide in which patients
invasive revascularization should be pursued.
In contrast, randomized clinical trial evidence suggests
that revascularization for stable CAD is not effective at
reducing cardiovascular events [4, 5]. This variation of
results in the literature has led to a degree of clinical
equipoise regarding the management of abnormal stress
testing, while funding for the International Study of
Comparative Health Effectiveness with Medical and In-
vasive Approaches (ISCHEMIA) trial is currently under-
way [6, 7]. In the absence of a clear clinical benefit,
patients and physicians may depend on other factors to
make clinical management decisions. Percutaneous re-
vascularization success has improved significantly since
its inception [8]. Patient choice and clinical factors, such
as renal disease and bleeding risk, may be barriers to the
use of a revascularization strategy.
To better understand decisions about the management
of abnormal MPI and patterns of revascularization, we
conducted this investigation in a population of patients
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with moderate to severe myocardial ischemia at a large
Veterans Affairs Medical Center. We hypothesized that
revascularization would be the predominant strategy and




We conducted a retrospective cohort study of patients at
a single academically affiliated Veterans Affairs Medical
Center who underwent MPI between December 2010 and
July 2011. The study protocol was reviewed by our Institu-
tional Review Board, which waived the requirement for in-
formed consent. Two cohorts were defined: 1) patients
with moderate or severe ischemia and 2) patients with
mild or no ischemia. Data for the subjects were retrieved
from the Veterans Affairs Computerized Patient Record
System and included demographics, baseline clinical char-
acteristics, and the results from their MPI. MPI results, in-
cluding the summed stress score, summed rest score,
summed difference score (SDS), and the final interpret-
ation of the MPI (e.g., normal or abnormal) were obtained.
We defined an SDS of 8 or greater as predictive of moder-
ate to severe ischemia.
MPI was conducted as either technetium-99m single
photon emission computed tomography combined with
either treadmill exercise stress or regadenoson vasodila-
tion or as rubidium-82 positron emission tomography
with regadenoson. The MPI results were interpreted by
an interdisciplinary team that included faculty from nu-
clear medicine, cardiology, and radiology. Reporting
standards for MPI were followed [9]. Any physician or
provider at our facility had the authority to order an
MPI, regardless of specialty.
Statistical analysis
The primary outcome of this study was to determine if
subjects with moderate to severe ischemia were more likely
to have a successful revascularization within 1 year after an
MPI than those with mild/no ischemia. We compared out-
comes using Chi-square tests. Baseline variables were com-
pared using the Mann-Whitney U tests and chi-squares as
appropriate. The secondary outcome was to compare the
rates of myocardial infarction (MI), between the two co-
horts at 1 year. Data were analyzed using SPSS version 21
(IBM, Armonk, NY). A P-value of <0.05 was predefined as
a significant difference. The Strengthening the Reporting
of Observational Studies in Epidemiology method was used
in the development of this investigation [10].
Results
Clinical characteristics
The study population was predominantly male, which is
typical of a Veteran population, and the median age was
63. Patients with no to mild ischemia (SDS < 8) were 64
(61–70) years, and patients with moderate to severe is-
chemia (SDS ≥ 8) were 63 (58–67) years (P = 0.07), there
has no significant difference between the two groups.
Clinical characteristics of the 544 veterans are summa-
rized in Table 1. Most baseline clinical variables were
not different between the two groups, but the moderate
to severe ischemia cohort was more likely to have CAD
or an abnormal ECG at baseline. Symptom burden (i.e.,
chest pain or dyspnea) was similar between the groups.
Of the total population, 39 (7.1%) had an SDS score of 8
or greater, and the median SDS was 11.
Outcomes
Patients with moderate to severe ischemia were more
likely to undergo coronary angiography (79.5% versus
9.5%, P < 0.0001) and successful revascularization (38.5%
vs. 4.0%, P < 0.0001, Table 1). Figure 1 demonstrates the
flow of patients through post-MPI management. Eight pa-
tients in the moderate to severe cohort did not undergo
left heart catheterization due to the improvement of
symptoms (n = 3), the clinician’s preference (n = 2), or the
patient declining angiography (n = 3). Of those in the
moderate to severe ischemia population who underwent
angiography, over half did not have a successful revascu-
larization (n = 16). In nearly all these 16 patients, their cor-
onary anatomy and disease process were not suitable for
mechanical revascularization due to chronic total occlu-
sion of the vessel or the anatomy from prior coronary ar-
tery bypass grafting (CABG) surgery that could not be
addressed percutaneously (Table 2). In only one case was
PCI attempted and failed, in all the others PCI was not
attempted. A small proportion of patients suffered an MI
(n = 6) within one year of the MPI, and that was more fre-
quent in the moderate to severe cohort (5.1% versus 0.8%
in the no to mild ischemia cohort, P = 0.01, Table 1).
Discussion
In this investigation, we demonstrated that moderate to
severe ischemia is uncommon in a contemporary nu-
clear cardiology laboratory. This finding is consistent
with a larger cohort spanning almost two decades, which
showed the prevalence of decreasing ischemia from 29.6%
in 1991 to 5.0% in 2009 [11]. The relative scarcity of not-
able ischemia introduces uncertainty regarding the utility
of widespread MPI testing. Professional societies and con-
sumer groups have addressed these questions through the
development of the Appropriate Use Criteria and the
Choosing Wisely campaign [12, 13].
We observed that patients with moderate to severe is-
chemia are more likely to undergo angiography than pa-
tients with mild/no ischemia. More importantly, we
observed that in this Veteran population with a high
prevalence of CAD, revascularization that was attempted
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was frequently unsuccessful. We also observed reasons
why revascularization was not pursued for some patients.
As previously noted, cohort data have suggested that
revascularization is superior to medical management in
patients with moderate to severe myocardial ischemia
[3]. Thus, our findings of the greater use of coronary
angiography in this cohort were not surprising. The not-
able finding from our investigation was that despite this
strong clinical preference, nearly half of this cohort was
not able to be revascularized. A variety of clinical
variables contribute to failure of coronary revasculariza-
tion, which include vessel tortuosity, plaque calcification,
and lesion location. Stenting within bypass grafts can be
challenging, and sometimes ischemia is related to a
chronic total vessel occlusion. When a low procedural
success rate is added to the costs and risks associated with
coronary angiography and revascularization, it may be rea-
sonable to first attempt to manage patients conservatively
with medical therapy, but these decisions need to be made
based on individualized patient care. Ample evidence also
suggests that cardiovascular risk factors such as smoking,
blood pressure, diet, and exercise are undertreated and are
more effective at reducing cardiovascular events.
We observed that even without a concerted effort at
medical therapy, some patients’ symptom profiles im-
proved after the MPI and no longer warranted revascu-
larization. Despite the presence of ischemia, both
physicians and patients in our cohort found reasons to
decline coronary angiography. Those that declined an-
giography were in the minority, and the opportunity to
improve decision-making likely exists. A survey of pa-
tients and cardiologists found widespread misunder-
standing of the benefits of revascularization among
patients, and although cardiologists demonstrated better
understanding of the benefits of revascularization, a sub-
stantial portion reported that they would perform revas-
cularization even in situations where they recognized
that there was no clinical benefit [14]. A wide variety of
medical therapies are available to reduce the symptoms
of angina, and shared decision-making tools are available
for guiding patients and physicians through revasculari-
zation options [15, 16].
A medical-therapy-first approach must be considered in
the context of the prognostic implications of moderate to






Age (year) 63(58–67) 64(61–70) 0.07
Clinical Characteristics [n(%)]
Chest pain 20(51.3) 248(49.1) 0.79
Dyspnea 15(38.5) 208(41.2) 0.74
CAD 29(74.4) 196(38.8) <0.0001
DM 17(43.6) 209(41.4) 0.79
HTN 30(76.9) 418(82.8) 0.36
HLD 34(87.2) 381(75.4) 0.10
Tobacco use 144(28.5) 8(20.5) 0.15
Obesity 21(53.8) 345(68.5) 0.06
Abnormal ECG 28(71.8) 266(52.7) 0.02
Outcomes [n(%)]
Coronary angiography 31(79.5) 48(9.5) <0.0001
Successful revascularization 15(38.5) 20(4.0) <0.0001
MI within 1 year 2(5.1) 4(0.8) 0.01
SDS Summed difference score, CAD Coronary artery disease, DM Diabetes mellitus,
HTN Hypertension, HLD Hyperlipidemia, ECG Electrocardiogram, MI Myocardial
infarction. Age is expressed as interquartile range (IQR)
Fig. 1 Patient flow diagram. Flowchart demonstrating the distribution of the two cohorts of patients and their clinical management after myocardial
perfusion imaging (MPI). SDS: Summed difference score, CABG: Coronary artery bypass graft, VA: Veterans affairs
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severe ischemia on an MPI. As with prior reports, we ob-
served a higher rate of MI at 1 year after an MPI was per-
formed within the moderate to severe cohort. While the
COURAGE trial did not show revascularization to be su-
perior at reducing cardiovascular events, a sub-study of
patients with serial MPIs showed that revascularization
was more effective than medical therapy at reducing the
ischemia burden. The relationship between myocardial is-
chemia and the pathophysiology of an MI is complex [6].
The highly anticipated ISCHEMIA trial (www.ischemia-
trial.org) should provide robust evidence on this import-
ant clinical management question.
Limitations
This retrospective investigation was performed in a large
VA health care center. The study population was predom-
inantly male; therefore, its generalizability to women or to
other non-VA academic centers is limited. As a non-
randomized trial, we cannot make any distinctions about
causality regarding the decisions to undergo revasculariza-
tion between the study cohorts, but can report data on de-
cisions as to why revascularization was not pursued in
some patients with ischemia. Decisions to pursue revascu-
larization need to be made on an individual basis, and our
findings are intended to describe contemporary practices
and not to discourage revascularization.
Conclusion
In relation to the amount of MPI tests that were ordered
within the Veteran population, moderate to severe ische-
mia was an uncommon finding. Among the patients
with ischemia, revascularization was typically attempted
and was frequently unsuccessful. Patient preferences and
therapy goals are important considerations for revascu-
larization and should ideally be addressed even before
an MPI is pursued.
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